Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15546918 
Obara Y, Labudda K, Dillon TJ, Stork PJ (2004) PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells. J Cell Sci 117, 6085-94 15546918
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S17-p - Src (human)
Orthologous residues
Src (human): S17‑p, Src (mouse): S17‑p, Src iso2 (mouse): S17‑p, Src (rat): S17‑p, Src (chicken): S17‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial), AtT20 (pituitary cell), CHO (fibroblast) [EphB1 (human), transfection], PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  hamster, human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
isoproterenol increase

T203-p - ERK1 (rat)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
PP2 forskolin, IBMX inhibit treatment-induced increase
cAMP analog increase
H-89 cAMP analog inhibit treatment-induced increase
PP2 cAMP analog inhibit treatment-induced increase
NGF increase
PP2 NGF inhibit treatment-induced increase
EGF increase
PP2 EGF inhibit treatment-induced increase

Y205-p - ERK1 (rat)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
PP2 forskolin, IBMX inhibit treatment-induced increase
cAMP analog increase
H-89 cAMP analog inhibit treatment-induced increase
PP2 cAMP analog inhibit treatment-induced increase
NGF increase
PP2 NGF inhibit treatment-induced increase
EGF increase
PP2 EGF inhibit treatment-induced increase

T183-p - ERK2 (rat)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
PP2 forskolin, IBMX inhibit treatment-induced increase
cAMP analog increase
H-89 cAMP analog inhibit treatment-induced increase
PP2 cAMP analog inhibit treatment-induced increase
NGF increase
PP2 NGF inhibit treatment-induced increase
EGF increase
PP2 EGF inhibit treatment-induced increase

Y185-p - ERK2 (rat)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
PP2 forskolin, IBMX inhibit treatment-induced increase
cAMP analog increase
H-89 cAMP analog inhibit treatment-induced increase
PP2 cAMP analog inhibit treatment-induced increase
NGF increase
PP2 NGF inhibit treatment-induced increase
EGF increase
PP2 EGF inhibit treatment-induced increase

S17-p - Src (rat)
Orthologous residues
Src (human): S17‑p, Src (mouse): S17‑p, Src iso2 (mouse): S17‑p, Src (rat): S17‑p, Src (chicken): S17‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
NGF increase
8-Rp-cAMP NGF inhibit treatment-induced increase
H-89 NGF inhibit treatment-induced increase
EGF no change compared to control
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced
 Effect of modification (process):  cell growth, altered

Y419-p - Src (rat)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IBMX, forskolin increase
H-89 forskolin, IBMX inhibit treatment-induced increase
NGF increase
H-89 NGF inhibit treatment-induced increase
EGF no change compared to control

Y499-p - TrkA (rat)
Orthologous residues
TrkA (human): Y496‑p, TrkA iso2 (human): Y490‑p, TrkA (mouse): Y499‑p, TrkA (rat): Y499‑p, TrkA iso2 (rat): Y493‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP2 no change compared to control
SU6656 decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.